Beam Therapeutics CEO Sells $739K of Stock Beam CEO Evans sold $739,000 of stock on Apr 6, 2026, per SEC Form 4 and Investing.com; institutional investors should normalize the sale to holdings and market cap.

Beam Therapeutics CEO Sells $739K of Stock: Beam CEO Evans sold $739,000 of stock on Apr 6, 2026, per SEC Form 4 and Investing.com; institutional investors should normalize the sale to holdings and market cap. 👈 Read full analysis #BeamTherapeutics #StockMarket #Investing #CEOCorner #FinancialNews

Beam Therapeutics CEO Evans Sells $1.1m Stock Beam Therapeutics CEO Evans sold $1.1m of stock (SEC Form 4 filed Apr 1, 2026), a disclosure event that is small relative to typical biotech market caps and requires contextual analysis.

Beam Therapeutics CEO Evans Sells $1.1m Stock: Beam Therapeutics CEO Evans sold $1.1m of stock (SEC Form 4 filed Apr 1, 2026), a disclosure event that is small relative to typical biotech market caps and requires… 👈 Read full analysis #BeamTherapeutics #Biotech #StockMarket #Investing #SECFilings

Beam Therapeutics stock surges after FDA grants RMAT designation Investing.com -- Beam Therapeutics Inc. (NASDAQ:BEAM) stock surged 12% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, its investigational cell therapy for sickle cell disease. The RMAT designation, which follows the orphan drug designation received earlier this year, provides Beam with opportunities for enhanced FDA collaboration, potential accelerated approval pathways, and possible priority review of future biologics license applications. This regulatory milestone recognizes BEAM-101’s potential as a one-time treatment for severe sickle cell disease. "We are thrilled that the FDA has granted RMAT designation to BEAM-101, following orphan drug designation earlier this year, reinforcing its potential as a one-time, best-in-class therapy for severe sickle cell disease," said Giuseppe Ciaramella, Ph.D., president of Beam Therapeutics. The company recently presented updated clinical data from its BEACON Phase 1/2 trial at the European Hematology Association Congress in June. Results from 17 treated patients showed robust increases in fetal hemoglobin, reductions in sickle hemoglobin, rapid cell engraftment, and improved markers of hemolysis and oxygen delivery. Notably, no vaso-occlusive crises were reported post-engraftment. Beam Therapeutics, which specializes in precision genetic medicines through base editing, has now dosed 30 patients in the BEACON trial and expects to present additional data later this year. The company’s manufacturing process for BEAM-101 utilizes an advanced, largely automated system that has consistently demonstrated high yields and viability. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With BEAM making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed BEAM alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including BEAM, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is BEAM poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #BeamTherapeutics #FDA #RMAT #SickleCellDisease #Investing

On the topic of the AATD-related arbitration with #BeamTherapeutics, #PrimeMedicine says AATD development candidate will include 'intentional' non-transition mutation, hence it does not infringe Beam's field which is transition-'only'.

Sounds reasonable.

Respiratory Weekly News – May 16th 2025 Lung & Respiratory Health Breakthroughs: IPF Patient Voices, Asthma Trial Success, Gene Editing Milestone & More 🫁💨 In this week’s […] The post Respiratory Weekly News – May 16th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Respiratory Weekly News – May 16th 2025 #News #AsthmaCare #BeamTherapeutics #biologics Comment below!

Beam Therapeutics and Prime Medicine Need to Unite Prime Medicine disclosed this week that they were in binding arbitration with Beam Therapeutics regarding their development of prime editin...

Paging David Liu... #BeamTherapeutics and #PrimeMedicine Need to Unite (blog) rnaitherapeutics.blogspot.com/2025/05/beam...

#CRISPR $BEAM $PRME

If #BeamTherapeutics felt safe, they would not have to haggle with #PrimeMedicine.

AATD could well illustrate that base editing might end up being a #transitory tech, eventually supplanted by the more versatile and specific prime editing. Just buy them.

Also, #PrimeMedicine is in binding arbitration with #BeamTherapeutics in whether they can pursue #AATD under their agreement.

Respiratory Weekly News – May 16th 2025 Lung & Respiratory Health Breakthroughs: IPF Patient Voices, Asthma Trial Success, Gene Editing Milestone & More 🫁💨 In this week’s […] The post Respiratory Weekly News – May 16th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Respiratory Weekly News – May 16th 2025 #News #AsthmaCare #BeamTherapeutics #biologics Comment below!

Respiratory Weekly News – May 16th 2025 Lung & Respiratory Health Breakthroughs: IPF Patient Voices, Asthma Trial Success, Gene Editing Milestone & More 🫁💨 In this week’s […] The post Respiratory Weekly News – May 16th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Respiratory Weekly News – May 16th 2025 #News #AsthmaCare #BeamTherapeutics #biologics Comment below!

#BeamTherapeutics got to wonder why #PrimeMedicine is going after AATD as well.

If Beam's base editing-LNPs good enough in terms of efficacy, is Prime spotting an opening in safety, e.g. bystander or esp Genevant-derived LNPs?

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administ... U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -...

Following on the heels of #VerveTherapeutics with VERVE-102, #BeamTherapeutics also got IND clearance from FDA for its #BaseEditing therapeutic: finance.yahoo.com/news/beam-th...